Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5679478 | 1.00 | ACHE (0.58) | ACHEDRD2DRD3POLBADRB3 | |
| SCHEMBL9518883 | 1.00 | ACHE (0.58) | ACHEDRD2DRD3POLBADRB3 | |
| Hydrochloric Acid SCHEMBL8765229 | 0.99 | ACHE (0.57) | ACHEDRD2DRD3POLBADRB3 | |
| Hydrochloric Acid SCHEMBL8765234 | 0.99 | ACHE (0.57) | ACHEDRD2DRD3POLBADRB3 | |
| Hydrochloric Acid SCHEMBL9443687 | 0.99 | ACHE (0.57) | ACHEDRD2DRD3POLBADRB3 | |
| SCHEMBL8765782 | 0.93 | ADRB3 (0.55) | ACHEDRD2DRD3POLBADRB3 | |
| SCHEMBL8766026 | 0.93 | GAA (0.50) | ACHEDRD2DRD3POLBADRB3 | |
| Hydrochloric Acid SCHEMBL8766863 | 0.91 | ADRB3 (0.51) | ACHEDRD2DRD3POLBADRB3 | |
| Hydrochloric Acid SCHEMBL8765354 | 0.89 | GAA (0.51) | ACHEPOLBADRB3GAANPSR1 | |
| SCHEMBL9305655 | 0.88 | BRD4 (0.60) | ACHEDRD2DRD3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0347313-B1 | 2-Amino-7-hydroxytetraline ethers | SANOFI ELF (FR) | 1993-12-15 | — | — | EP | claimed |
| US-5159103-A | 2-amino-7-hydroxytetraline ethers | SANOFI (FR) | 1992-10-27 | — | — | US | claimed |
| EP-0347313-A2 | 2-Amino-7-hydroxytetraline ethers | ELF SANOFI (FR) | 1989-12-20 | — | — | EP | claimed |
| US-7030160-B2 | Propanolaminotetralines, preparation thereof and compositions containing same | SANOFI-AVENTIS (FR) | 2006-04-18 | — | — | US | disclosed |
| US-20040034070-A1 | Propanolaminotetralines, preparation thereof and compositions containing same | SANOFI-AVENTIS (FR) | 2004-02-19 | — | — | US | disclosed |
| EP-1292572-B1 | PROPANOLAMINOTETRALINES, PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | SANOFI SYNTHELABO (FR) | 2004-02-18 | — | — | EP | disclosed |
| EP-1292572-A1 | PROPANOLAMINOTETRALINES, PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2003-03-19 | — | — | EP | disclosed |
| US-6391915-B2 | ANTIULCER AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-21 | — | — | US | disclosed |
| US-20020006956-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-17 | — | — | US | disclosed |
| WO-2001094307-A1 | PROPANOLAMINOTETRALINES, PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2001-12-13 | — | — | WO | disclosed |
| EP-0976720-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-02-02 | — | — | EP | disclosed |
| EP-0579833-B1 | ETHANOLAMINE DERIVATIVES WITH ANTI-POLLAKIURIA ACTIVITY | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-20 | — | — | EP | disclosed |
| EP-0579833-A1 | ETHANOLAMINE DERIVATIVES WITH ANTI-POLLAKIURIA ACTIVITY. | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-01-26 | — | — | EP | disclosed |
| EP-0347313-B1 | 2-Amino-7-hydroxytetraline ethers | SANOFI ELF (FR) | 1993-12-15 | — | — | EP | disclosed |
| WO-1992018461-A1 | ETHANOLAMINE DERIVATIVES WITH ANTI-POLLAKIURIA ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-29 | — | — | WO | disclosed |
| EP-0347313-A2 | 2-Amino-7-hydroxytetraline ethers | ELF SANOFI (FR) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006956-A1 | Propanolamine derivatives | PNLIP, ADRB1, FABP2 | ACHE 78/4885DRD2 115/4885DRD3 103/4885 |
| US-20040034070-A1 | Propanolaminotetralines, preparation thereof and compositions containing same | ADRB3, ADRB1, ADRB2 | ACHE 79/4885DRD2 386/4885DRD3 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.